Searched for
PHARMA TARIFF
India's defence export boom could hit ₹65,000 crore by 2030; pvt sector startups the real play: Sunil SubramaniamIndia's defence exports are poised to surpass government targets, reaching ₹60,000-65,000 crore by 2030, according to market expert Sunil S...- India, Uzbekistan aim to double bilateral trade in 3 yearsIndia and Uzbekistan are set to significantly boost bilateral trade, aiming to double it within three years. Discussions at the recent Inte...
- 'Fastest we've ever put a trade deal into force': British High Commissioner to India Lindy Cameron hails India-UK trade dealThe India-UK Comprehensive Economic and Trade Agreement (CETA) will take effect on July 15, 2026, marking the fastest trade deal implementa...
- These large-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of up to 27%As the market seems to be in comeback mode, it helps to be aware that the best (and probably biggest) wealth creator of the last couple of ...
- 'Not a great environment for Indian market': Harsha Upadhyaya on Iran-US tensions, IT outlook, pharma bet, and where to be cautiousGlobal challenges are impacting Indian stocks. West Asian tensions and rising US inflation create headwinds. Tech sector shifts also affect...
- Sweet pills: How pharma stocks delivered bumper returns to Indian investors, defying 2026 whiplashIndian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...
- Pharma exports to US seen muted this yearIndian pharma exports to the US face a subdued outlook this year. Policy uncertainties, falling generic prices, and regional conflicts are ...
- India-Oman CEPA kicks in June 1: What gets cheaper, which sectors gain, and key benefits explainedIndia's Comprehensive Economic Partnership Agreement with Oman comes into effect on June 1, granting New Delhi 100% duty-free access for 98...
- 30 Nifty stocks wipe out Rs 22.64 lakh crore investor wealth in 2026 so far; HDFC Bank, TCS lead routThirty Nifty 50 stocks have wiped out Rs 22.64 lakh crore in investor wealth this year. HDFC Bank and TCS led the decline, losing Rs 3.55 l...
- Long-term Investing: Ecosystem with an edge called India; 12 large- mid- and small-cap stocks with upside potential of up to 34%Tactical investing should not be confused with long-term investing. In a world where geopolitical risk, commodity shocks, and uncertainty a...
- Nifty to trade in 28,000–30,000 range in FY27 led by earnings: Smallcase managersSmallcase managers remain optimistic on India’s equity markets despite the Nifty declining over 9% this year, projecting the benchmark inde...
- Market will be volatile, look for an alternative solution: 5 large-caps from different sectors with upside potential of up to 30%A fall in crude oil prices can trigger a relief rally, which in fact it did in early trade on Thursday. But there is another reality as wel...
- Laurus Labs adds Rs 40,150 crore to investors' wealth in a year with 120% rally. Buy, hold or book profits?Laurus Labs has significantly boosted investor wealth, adding over Rs 40,000 crore in a year with a 120% stock rally. Driven by business im...
- Smallcaps rally! IIFL Finance, Hindustan Copper, Meesho, other stocks jump up to 7%Smallcap stocks, including IIFL Finance, Meesho, and GRSE, surged up to 7% on Wednesday, outperforming benchmark indices. This rally occurr...
- Secular, cyclical or war-dependent: A ratio to tell you what kind of growth you are buying. 6 stocks with upside potential of up to 29%Some valuation ratios are used because they are easy. The PE ratio is one of them. It is simple, familiar, and convenient. Not only for the...
- Additional US tariffs on Indian goods since April 2025: Here’s the full timelineThe United States imposed a series of tariffs on Indian goods starting April 2025. These duties varied, with some being reciprocal and othe...
- Pharma exports surpass $31 billion in FY26 despite global headwindsIndian pharmaceutical exports reached over $31 billion in FY26. March saw a significant 23% drop, primarily due to a slowdown in the United...
- Compliance squeeze, global scrutiny redefine India’s $30 billion pharma export playbookAs global markets prioritise quality and regulatory trust, India’s pharma sector is recalibrating beyond its traditional cost advantage.
- India–New Zealand $20 billion FTA: List of sectors set to gain ground as the deal kicks inIndia and New Zealand have signed a Free Trade Agreement. This pact offers zero-duty access for most Indian exports. Key sectors like texti...
- Sun's strong gravity helps India Inc's pullSun Pharma has expanded its horizons by acquiring Organon, a notable New Jersey pharmaceutical firm. This strategic acquisition fortifies S...
Load More
